scholarly journals Specific Hyposensitization for Atopic Dermatitis: A New Era?

Dermatology ◽  
1991 ◽  
Vol 182 (2) ◽  
pp. 71-72 ◽  
Author(s):  
J.-H. Saurat
Keyword(s):  
Atopic Dermatitis ◽  
New Era ◽  
Specific Hyposensitization

scholarly journals New era of biologic therapeutics in atopic dermatitis

2013 ◽  
Vol 13 (4) ◽  
pp. 549-561 ◽  
Author(s):  
Emma Guttman-Yassky ◽  
Nikhil Dhingra ◽  
Donald YM Leung
Keyword(s):  
Atopic Dermatitis ◽  
New Era

scholarly journals Itch in Atopic Dermatitis – What Is New?

2021 ◽  
Vol 8 ◽  
Author(s):  
Franz J. Legat
Keyword(s):  
Atopic Dermatitis ◽  
Intracellular Signaling ◽  
Sleep Disturbances ◽  
Skin Diseases ◽  
Immunosuppressive Agents ◽  
Calcineurin Inhibitors ◽  
Inflammatory Skin Diseases ◽  
New Era ◽  
Short And Long Term ◽  
Chronic Pruritus

Atopic dermatitis (AD) is among the most frequent inflammatory skin diseases in humans, affecting up to 20% of children and 10% of adults in higher income countries. Chronic pruritus is a disease-defining symptom of AD, representing the most burdensome symptom for patients. Severe chronic pruritus causes significant sleep disturbances and impaired quality of life, as well as increased anxiety, depression and suicidal behavior. Until recently, skin care, topical corticosteroids, and calcineurin-inhibitors were primarily used to treat mild to moderate AD, while phototherapy and immunosuppressive agents such as corticosteroids, cyclosporine, and methotrexate were used to treat patients with moderate to severe AD. The potential short- and long-term adverse events associated with these treatments or their insufficient therapeutic efficacy limited their use in controlling pruritus and eczema in AD patients over longer periods of time. As our understanding of AD pathophysiology has improved and new systemic and topical treatments have appeared on the market, targeting specific cytokines, receptors, or their intracellular signaling, a new era in atopic dermatitis and pruritus therapy has begun. This review highlights new developments in AD treatment, placing a specific focus on their anti-pruritic effects.

scholarly journals New Cytokines in the Pathogenesis of Atopic Dermatitis—New Therapeutic Targets

2018 ◽  
Vol 19 (10) ◽  
pp. 3086 ◽  
Author(s):  
Jolanta Klonowska ◽  
Jolanta Gleń ◽  
Roman Nowicki ◽  
Magdalena Trzeciak
Keyword(s):  
Quality Of Life ◽  
Atopic Dermatitis ◽  
Atopic Diseases ◽  
Biologic Therapies ◽  
Inflammatory Skin Disease ◽  
Biological Drugs ◽  
New Era ◽  
To Receive ◽  
Therapeutic Possibilities

Atopic dermatitis (AD) is a recurrent, chronic, and inflammatory skin disease, which processes with severe itchiness. It often coexists with different atopic diseases. The number of people suffering from AD is relatively high. Epidemiological research demonstrates that 15–30% of children and 2–10% adults suffer from AD. The disease has significant negative social and economic impacts, substantially decreasing the quality of life of the patients and their families. Thanks to enormous progress in science and technology, it becomes possible to recognise complex genetic, immunological, and environmental factors and epidermal barrier defects that play a role in the pathogenesis of AD. We hope that the new insight on cytokines in AD will lead to new, individualised therapy and will open different therapeutic possibilities. In this article, we will focus on the cytokines, interleukin (IL)-17, IL-19, IL-33, and TSLP (thymic stromal lymphopoietin), which play a significant role in AD pathogenesis and may become the targets for future biologic therapies in AD. It is believed that the new era of biological drugs in AD will give a chance for patients to receive more successful treatment.

Specific hyposensitization in atopic dermatitis

1979 ◽  
Vol 101 (6) ◽  
pp. 697-700 ◽  
Author(s):  
MARIA C. DI PRISCO FUENMAYOR ◽  
R.H. CHAMPION
Keyword(s):  
Atopic Dermatitis ◽  
Specific Hyposensitization

scholarly journals The New Era of Biologics in Atopic Dermatitis: A Review

2021 ◽  
pp. e2021144
Author(s):  
Simon Schneider ◽  
Linda Li ◽  
Alexander Zink
Keyword(s):  
Atopic Dermatitis ◽  
Skin Disorder ◽  
Treatment Options ◽  
Therapeutic Approaches ◽  
New Era ◽  
Therapy Options ◽  
The Past ◽  
Age Dependent ◽  
Distinct Individual ◽  
Inflammatory Skin Disorder

Atopic dermatitis (AD) is a prevalent inflammatory skin disorder affecting all ages and ethnic groups. The age-dependent varying appearance and extent of pruritic lesions are accompanied by distinct individual suffering, highlighting the importance of effective treatment options. Over the past years, systemic drugs have considerably extended therapeutic approaches of patients with moderate to severe AD, in particular, new biologics, most notably dupilumab has appeared as major breakthrough. In addition to monoclonal blockade of IL-4 and IL-13 pathway, more cytokines have been found to play a substantial role in AD pathogenesis, presenting potential targets for new therapy options.  

scholarly journals Soluble Factors and Receptors Involved in Skin Innate Immunity—What Do We Know So Far?

Biomedicines ◽  
2021 ◽  
Vol 9 (12) ◽  
pp. 1795
Author(s):  
Lucian G. Scurtu ◽  
Olga Simionescu
Keyword(s):  
Pattern Recognition ◽  
Innate Immunity ◽  
Atopic Dermatitis ◽  
Antimicrobial Peptides ◽  
Complement System ◽  
Soluble Factors ◽  
New Era ◽  
High Interest ◽  
Cytokine Inhibitors ◽  
Neoplastic Disorders

The pattern recognition receptors, complement system, inflammasomes, antimicrobial peptides, and cytokines are innate immunity soluble factors. They sense, either directly or indirectly, the potential threats and produce inflammation and cellular death. High interest in their modulation has emerged lately, acknowledging they are involved in many cutaneous inflammatory, infectious, and neoplastic disorders. We extensively reviewed the implication of soluble factors in skin innate immunity. Furthermore, we showed which molecules target these factors, how these molecules work, and how they have been used in dermatological practice. Cytokine inhibitors have paved the way to a new era in treating moderate to severe psoriasis and atopic dermatitis.

scholarly journals New Era in Atopic Dermatitis Treatment: Results of Long-Term Dupilumab Administration

2021 ◽  
Vol 20 (5) ◽  
pp. 390-395
Author(s):  
Nikolay N. Murashkin ◽  
Leonid A. Opryatin ◽  
Roman V. Epishev ◽  
Alexander I. Materikin ◽  
Eduard T. Ambarchyan ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Skin Inflammation ◽  
Efficacy And Safety ◽  
Barrier Dysfunction ◽  
Treatment Results ◽  
New Era ◽  
Short And Long Term ◽  
Chronic Skin

Atopic dermatitis (AD) is a disease characterized by chronic skin inflammation and epidermal barrier dysfunction leading to decrease in patients' quality of life. AD is widespread in general population including children. This article covers the disease pathophysiological mechanisms including those that depend on the endotype, as well as core principles of systemic therapy for children with moderate and severe AD. Features of targeted therapy of such patients with dupilumab (IL-4 and IL-13 inhibitor) are presented. The studies' results on dupilumab efficacy and safety in the short- and long-term are shown.

scholarly journals A new era has begun: Treatment of atopic dermatitis with biologics

2021 ◽  
Vol 5 (01) ◽  
pp. 265-273
Author(s):  
Dora Stölzl ◽  
Stephan Weidinger ◽  
Katharina Drerup
Keyword(s):  
Atopic Dermatitis ◽  
New Era
Sign in / Sign up

Export Citation Format

Share Document